“…14,52,53 It is very important to consider the administration of LVX in patients with CKD and alterations in TSH for a greater benefit in decreasing proteinuria, thus adding the correlation that thyroid hormone in endothelial damage and in cardiovascular risk could also decrease mortality and decrease eGFR. 14,20,52,54 In our study, eGFR increased in the LVX group by 4 ml/min per 1.73 m 2 , compared to that in the placebo group, in which eGFR decreased by 2 ml/min per 1.73 m 2 . Van Welsem et al 9 reported that the normalization of hypothyroidism after treatment with LVX led to a significant improvement in renal function in a patient with CKD.…”